Meeting in Washington, DC, USA, 30-31 March 1999: Serine/threonine phosphorylation in cytokine signal transduction

Leukemia

Volumn 14, Issue 1, 2000, Pages 9-21

  McCubrey, J A ^a   Stratford May, W ^b   Duronio, V ^c   Mufson, A ^d  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Chemotherapeutic drugs; Cytokine; Phosphorylation; Signal transduction

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; SERINE; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR; THREONINE; TRANSCRIPTION FACTOR;

CANCER; CELL DEATH; CONFERENCE PAPER; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PHOSPHORYLATION; REVIEW;

ANIMALS; CYTOKINES; HUMANS; PHOSPHORYLATION; SERINE; SIGNAL TRANSDUCTION; THREONINE;

EID: 0033630308     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401657     Document Type: Conference Paper

References (141)

1. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcription activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
2. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol 1995; 60: 1-35.
3. Lamer AC, David M, Feldman GM, Igarashi K, Hackett RH, Webb DS, Sweitzer SM, Petricoin EF III, Finbloom DS. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 1993; 261: 1730-1733.
4. Lamer AC, Finbloom DS. Protein tyrosine phosphorylation as a mechanism which regulates cytokine activation of early response genes, Biochim Biophys Acta 1995; 1266: 278-287.
5. Finbloom DS. Larner AC. Induction of early response genes by interferons, interleukins, and growth factors by the tyrosine phosphorylation of latent transcription factors. Implications for chronic inflammatory diseases. Arthr Rheum 1995; 38: 877-889.
6. Finbloom DS, Larner AC. Regulation of the Jak/STAT signalling pathway. Cell Signal 1995; 7: 739-745.
7. Kapur R, Everett ET, Uffmann J, McAndrews-Hill M, Cooper R, Ryder J, Vik T, Williams DA. Overexpression of human stem cell factor impairs melanocyte, mast cell, and thymocyte development: a role for receptor tyrosine kinase-mediated mitogen activated protein kinase activation in cell differentiation. Blood 1997; 90: 3018-3026.
8. Kapur R, Majumdar M, Xiao X, McAndrews-Hill M, Schindler K, Williams DA. Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. Blood 1998; 91: 879-889.
9. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 1998; 10: 233-239.
10. Craddock BL, Welham MJ. Interleukin-3 induces association of the protein-tyrosine phosphatase SHP2 and phosphatidylinositol 3-kinase with a 100-kDa tyrosine-phosphorylated protein in hematopoietic cells. J Biol Chem 1997; 272: 29281-29289.
11. Anderson SM, Burton EA, Koch BL. Phosphorylation of Cb1 following stimulation with interleukin-3 and its association with Grb2, Fyn and phosphatidylinositol 3-kinase. J Biol Chem 1997; 272: 739-745.
12. Minshall C, Arkins S. Freund GG, Kelly KW. Requirement for phosphatidylinositol-3-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. J Immunol 1996; 156: 939-947.
13. Kubota Y, Angelotti T, Niederfellner G, Herbst R, Ullrich A. Activation of phosphatidlyinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases. Cell Growth Differ 1998; 9: 247-256.
14. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997; 22: 267-272.
15. Pullen N, Thomas G. The modular phosphorylation and activation of p70S6K. FEBS Lett 1997; 410: 78-82.
16. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-267.
17. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95: 11211-11216.
18. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA 1998; 95: 7439-7444.
19. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not Bcl-xL. Cell 1996; 87: 619-628.
20. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
21. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
22. Scheid MP, Duronio V. Phosphatidylinositol 3-OH kinase activity is not required for activation of mitogen-activate protein kinase by cytokines. J Biol Chem 1996; 271: 18134-18139.
23. Scheid MP, Schubert KM, Duronio V. Regulation of Bad phosphorylation and association with Bcl-xL by the MAPK/ERK kinase. J Biol Chem 1999; 274: 31108-31113.
24. Scheid MP, Lauener RW, Duronio V. Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocylemachrophage colony-stimulating factor. Biochem J 1995; 312: 159-162.
25. Craddock BL, Orchiston EA, Hinton HJ, Welham MJ. Dissociation of apoptosis from proliferation, protein kinase B activation, and Bad phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling. J Biol Chem 1999; 274: 10633-10640.
26. Hinton HJ, Welham MJ. Cytokine-induced protein kinase B activation and Bad phosphorylation do not correlate with cell survival of hematopoietic cells. J Immunol 1999; 162: 7002-7009.
27. Wennstrom S, Downward J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 1999; 19: 4279-4288.
28. Sutor SL, Vroman BT, Armstrong EA, Abraham RT, Karnitz LM. A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates C-Raf and A-Raf. J Biol Chem 1999; 274: 7002-7010.
29. Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW, Krystal G. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA 1996; 93: 1689-1693.
30. Huber M, Helgason CD, Scheid MP, Duronio V, Humphries RK, Krystal G. Targeted disruption of SHIP leads to steel factor-induced degranulation of mast cells. EMBO J 1998; 17: 7311-7319.
31. David M, Petriroin E, Benjamin C, Pine R, Weber MJ, Larner AC. Requirement for MAP kinase (ERK2) activity in interferon alpha-and interferon beta-stimulated gene expression through Stat proteins. Science 1995; 269: 1721-1723.
32. Sakatsume M, Stantcato LF, David M, Silvennoinen O, Saharinen P, Pierce J, Larner AC, Finbloom DS. Interferon gamma activation of Raf-1 is Jak1-dependent and p21 ras-independent. J Biol Chem 1998; 273: 3021-3026.
33. Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF, Krolewski JJ, Silvennoinen O, Saharinen P, Pierce J, Marshall CJ, Sturgill T, Finbloom DS, Larner AC. Beta interferon and oncoslatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 1997; 17: 3833-3840.
34. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997; 16: 293-297.
35. Wojnowski L, Stancato LF, Zimmer AM, Hahn H, Beck TW, Larner AC, Rapp UR, Zimmer A. c-raf-1 protein kinase is essential for mouse development. Mech Dev 1998; 76: 141-149.
36. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-83.
37. Chaturvedi P, Reddy MV, Reddy EP. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 1998; 16: 1749-1758.
38. Jain N, Zhang T, Fong SL, Lim CP, Cao X. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene 1998; 17: 3157-3167.
39. Stancato LF, Yu CR, Petricoin EF III, Larner AC. Activation of Raf-1 by interferon gamma and oncoslatin M requires expression of the Stat1 transcription factor. J Biol Chem 1998; 273: 18701-18704.
40. McCubrey JA, Steelman LS, Hoyle PA, Blalock WL, Weinstein-Oppenheimer CR, Franklin RA, Cherwinski H, Bosch E, McMahon M. Differential abilities of activated Rat oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12: 1903-1929.
41. Mayo MW, Wang X-Y, Algate PA, Arana GF, Hoyle PE, Steelman LS, McCubrey JA. Synergy between AUUUA motif disruption and enhancer insertion results in autocrine transformation of interleukin-3-dependent hemalopoielic cells. Blood 1995; 86: 3139-3150.
42. Wang X-Y, McCubrey JA. Malignant transformation induced by cytokine genes: a comparison of the abilities of germline and mutated interleukin 3 genes to transform hematopoietic cells by transcriptional and post-transcriptional mechanisms, Cell Growth Differ 1996; 7: 487-500.
43. Wang XY, McCubrey JA. Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation. Leukemia 1997; 11: 1711-1725.
44. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells, possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13: 1109-1116.
45. Pritchard CA, Bolin L, Slattery R, Murray RL, McMahon M. Postnatal lethality and neurological and gastrointestinal detects in mice with targeted disruption of the A-Raf protein kinase. Curr Biol 1996; 6: 614-617.
46. Samuels ML, Weber MJ, Bishop JM, McMahon M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase. Mol Cell Biol 1993; 13: 6241-6252.
47. Pritchard CA, Samuels ML, Bosch F, McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH-3T3 cells. Mol Cell Biol 1995; 13: 9410-9442.
48. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/Cdk complexes, Genes Dev 1997; 11: 663-677.
49. p. Mol Cell Biol 1997; 17: 5598-5611.
50. Van M, Dai T, Peak JC, Kyriakis JM. Zon LI, Woodgett JR, Templeton DJ. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 1994; 372: 798-800.
51. Lin A, Minden A, Martinetto H, Claret FX, Lange-Charter C, Mercurio F. Johnson GL, Karin M. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 1995; 268: 286-290.
52. Karin M, Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK Science 1994; 266: 1719-1723.
53. Xu S, Robbins D, Frost J, Dang A, Lange-Carter C, Cobb MH. MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 1995; 92: 6808-6812.
54. Johnson NL, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI, Johnson GL. Signal transduction pathways regulated by mitogen-artivated/extracellular response kinase kinase kinase induce cell death. J Biol Chem 1996; 271: 3229-3237.
55. Zanke BW, Ruble EA, Winnett E, Chan J, Randall S, Parsons M, Boudreau K, McInnis M, Yan M, Templeton DJ, Woodgett JR. Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes. J Biol Chem 1996; 271: 29876-29881.
56. Man J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265: 808-811.
57. Meier R, Rous J, Cuenda A, Nebreda AR, Cohen P. Cellular stresses and cytokines activate multiple mitogen-activated-protein kinase kinase homologues in PC12 and KB cells. Euro J Biochem 1996; 236: 796-80.5.
58. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993; 7: 2135-2148.
59. Lange-Carter CA, Johnson GL. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 1994; 265: 1458-1461.
60. Wang XZ, Ron D. Stress-induced phosphorylation and activation of CHOP (GADD153) by p38 MAP kinase. Science 1996; 272: 1347-1349.
61. Williams JG, Roberts TM. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metast Rev 1994; 13: 105-116.
62. McIlroy I, Chen D, Wjasow C, Michaeli T, Backer JM. Specific activation of p85-p110 phosphatidylinositol 3′-kinase stimulates DNA synthesis by Ras-and p70 S6 kinase-dependent pathways. Mol Cell Biol 1997; 17: 248-255.
63. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3′kinase: one of the effectors of Ras. Phil Trans Roy Soc London Series B: Biol Sci 1996; 351: 225-231.
64. Edelmann HM, Kuhne C, Petritsch C, Ballon I.M. Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in Swiss mouse 3T3 fibroblasts. J Biol Chem 1996; 271: 963-971.
65. Blenis J, Grammer T. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997; 14: 1635-1642.
66. Lenormand P, McMahon M, Pouyssegur J. Oncogenic Raf-1 activates the p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. J Biol Chem 1996; 271: 15762-15768.
67. Gelfand EW, Ishizuka T, Oshiba A, Sakata N, Terada N, Johnson GL. Aggregation of the Fc∈RI on mast cells stimulates c-Jun amino-terminal kinase activity. J Biol Chem 1996; 271: 12762-12766.
68. Calvo V, Wood M, Gjertson C, Vik T, Bierer BE. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. Eur J Immunol 1994; 24: 2664-2671.
69. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 975-977.
70. Sugiyama H, Papst P, Gelfand EW, Terada N. p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229. J Immunol 1996; 157: 656-660.
71. Terada N, Franklin RA, Lucas JJ, Blenis J, Gelfand EW. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J Biol Chem 1993; 268: 12062-12068.
72. Thomas G, Hall MN. Tor signalling and control of cell growth. Curr Opin Cell Biol 1997; 9: 782-787.
73. Sigal NH, Dumont FJ, Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519-560.
74. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 1998: 17: 1415-1438.
75. Gorvel JP, Chang TC, Boretto J, Azuma T, Chavrier P. Differential properties of D4/LyGDI versus RhoGDI: phosphorylation and rho GTPase selectivity. FEBS Lett 1998; 422: 269-273.
76. Roberts A, Kim C, Zhen L, Lowe J, Kapur R, Petryniak B, Spaetti A, Pollock J, Borneo J, Bradford GB, Atkinson SJ, Dinauer MC, Williams DA. Deficiency of the hematopoietic cell-specific Rho-family GTPase, Rac2, is characterized by multiple abnormalities in neutrophil function and impaired host defense. Immunity 1999; 10: 183-196.
77. Reddy BS, Simi B, Patel N, Aliaga C, Rao CV. Effect of amount and types of dietary fat on intestinal bacterial 7 alpha-dehydroxylase and phosphatidylinosilol-specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Cancer Res 1996; 56: 2314-2320.
78. Murray NR, Davidson LA, Chapkin RS, Gustafson WC, Schattenberg DG, Fields AP. Overexpression of protein kinase C bII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999; 145: 699-711.
79. Davidson LA, Lupton JR, Jiang YH, Chang WC, Aukema HM, Chapkin RS. Dietary fat and fiber alter rat colonic protein kinase C isozyme expression. J Nutrit 1995; 125: 49-56.
80. Lafave LM, Kumarathasan P, Bird RP. Effect of dietary fat on colonic protein kinase C and induction of aberrant crypt foci. Lipids 1994; 29: 693-700.
81. Mufson RA. The role of serine/threonine phosphorylation in hematopoietic cytokine receptor signal transduction. FASEB J 1997; 11: 37-44.
82. Rao P, Kitamura T, Miyajima A, Mufson RA. Human IL-3 receptor signaling: rapid induction of phosphatidylcholine hydrolysis is independent of protein kinase C but dependent on tyrosine phosphorylation in transfected NIH 3T3 cells. J Immunol 1995; 154: 1664-1674.
83. Rinaudo MS, Su K, Falk LA, Halder S, Mufson RA. Human interleukin-3 receptor modulates bcl-2 mRNA and protein level: through protein kinase C in TF-1 cells. Blood 1995; 86: 80-68.
84. Mufson RA, Gubina E, Rinaudo M, Baxter G. A phosphatidylcholine phospholipase C inhibitor, D609, blocks interleukin-3 (IL-3)-induced bcl-2 expression but not c-myc expression in human IL-3-dependent cells. Exp Cell Res 1998; 240: 228-235.
85. Gubina E, Rinaudo MS, Szallasi Z, Blumberg PM, Mufson RA. Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression. Blood 1998; 91: 823-829.
86. Sakamoto KM, Mignacca RC Gasson JC. Signal transduction by granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors. Recept Channels 1994; 2: 175-181.
87. Kwon EM, Sakamoto KM. The molecular mechanism of action of granulocyte-macrophage/colony-stimulating factor. J Invest Med 1996; 44: 442-446.
88. Lee HJ, Mignacca RC, Sakamoto KM. Transcriptional activation of egr-1 by granulocyte-macrophage colony-stimulating factor but not interleukin 3 requires phosphorylation of cAMP response element-binding protein (CREB) on serine 133. J Biol Chem 1995; 270: 15979-15983.
89. Wong A, Sakamoto KM. Granulocyte-macrophage colony-stimulating factor induces the transcriptional activation of egr-1 through a protein kinase A-independent signaling pathway. J Biol Chem 1995; 270: 30271-30273.
90. Watanabe S, Kubota H, Sakamoto KM, Arai K. Characterization of cis-acting sequences and trans-acting signals regulating early growth response 1 and c-fos promoters through the granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. Blood 1997; 89: 1197-1206.
91. Mignacca RC, Lee HJ, Kwon EM, Sakamoto KM. Mechanism of transcriptional activation of the immediate early gene Egr-1 in response to PIXY321. Blood 1996; 88: 848-854.
92. Sakamoto KM, Fraser JK, Lee HJ, Lehman E, Gasson JC. Granulocyte-macrophage colony-stimulating factor and interleukin-3 signaling pathways converge on the CREB-binding site in the human egr-1 promoter. Mol Cell Biol 1994; 14: 5975-5985.
93. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nature Med 1999; 5: 444-447.
94. Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 1999; 162: 4472-4481.
95. Frank DA, Robertson MJ, Bonni A, Ritz J, Greenberg ME. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci USA 1995; 92: 7779-7783.
96. Frank DA, Varticovski L. BCR/ABL leads to the constitutive activation of Stat proteins, shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996; 10: 1724-1730.
97. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) protein in hematopoietic cells lines transformed by Bcr/AB1. J Exp Med 1996; 183: 811-820.
98. Karras JG, Wang Z, Huo L, Howard RG, Frank DA, Rothstein TL. Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med 1997; 185: 1035-1042.
99. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lympocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997; 100: 3140-3148.
100. Pott C, Hiddemann W. Purine analogs in the treatment of chronic lympocytic leukemia. Leukemia 1997; 11: S25-S28.
101. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84: 443-450.
102. Simpson SJ, Shall S, Comiskey M, de Jong YP, Wang B, Mizoguchi E, Bhan AK, Terhorst C. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcrription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 1998; 187: 1225-1234.
103. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kihimoto T, Akira S. Targeted disruption of the mouse Stat3 gene leads to embryonic lethality. Proc Natl Acad Sci USA 1997; 94: 3801-3804.
104. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996; 157: :3220-3222.
105. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313-319.
106. Feldman GM, Rosenthal LA, Liu X, Hayes MP, Wynshaw-Boris A, Leonard WJ, Hennighausen L, Finbloom DS. STAT5-deficient mice demonstrate in granulocyte-macrophage colony-stimulating factor-induce proliferation and gene expression. Blood 1997; 90: 1768-1776.
107. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle J. Stat 5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841-850.
108. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KCF, Yin L, Pennica D, Johnson EM, Schreiber RD. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373-383.
109. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine J-C, Teglund S, Vanin EF, Bodner S, Colamoniri OR, van Deurson JM, Grosveld G, Ihle JN. Jak2 is essential for signalling through a variety of cytokine receptors. Cell 1998; 93: 385-395.
110. Thomis DC, Lee W, Berg LJ. T cells from Jak3-deficient mice have intact TCR, but increased apoptosis. J Immunol 1997; 159: 4708-4719.
111. Sohn SJ, Forbush KA, Nguyen N, Witthuhn B, Nosaka T, Ihle JN, Perlmutter RM. Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis. J Immunol 1998; 160: 2130-2138.
112. Pericle F, Kirken RA, Bronte V, Sconocchia G, DaSilva L, Segal DM. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. J Immunol 1997; 159: 2580-2585.
113. Pericle F, Pinto LA, Hicks S, Kirken RA, Sconocchia G, Rusnak J, Dolan MJ, Shearer G, Segal DM. HIV-1 infection induces a selective reduction in STAT5 protein expression. J Immunol 1998; 160: 28-31.
114. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 and Ser730 of Stata in prolactin-sensistive cells. J Biol Chem 1998; 273: 30218-30224.
115. Kirken RA, Malabarba MG, Xu J, Liu X, Farrar WL, Mennighausen L, Larner AC, Grimley PM, Rui H. Prolactin stimulates serine/lyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem 1997; 272: 14098-14103.
116. Kirken RA, Malabarba MG, Xu J, DaSilva RA, Liu X, Hennighausen L, Rui H, Farrar WL. Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase. J Biol Chem 1997; 272: 15459-15465.
117. Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for the regulation of mitosis. Nature 1996; 380: 544-547.
118. Shen M, Stukenberg PT, Kirschner MW, Lu KP. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev 1998; 12: 706-720.
119. Lu P-J, Zhou XZ, Shen M, Lu KP. Function of WW domains as phosphoserine or phosphothreonine-binding modules. Science 1999; 283: 1325-1328.
120. Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 1997; 89: 875-886.
121. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Raffeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, Cantley LC, Lu KP. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997; 278: 1957-1960.
122. Shen M, Vogt V, Haggblom C, Hunter T, Lu KP. Characterization and cell cycle regulation of related human telomeric proteins Pin2 and TRF1 suggests a role in mitosis. Proc Natl Acad Sci USA 1997; 94: 13618-15622.
123. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997; 57: 130-135.
124. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Rat-1 to mitochondria. Cell 1996; 87; 629-658.
125. Thompson CB, Gajewski TF. Apoptosis meets signal transduction: elimination of a Bad influence. Cell 1996; 87: 589-592.
126. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Ainne-Sempe C, Brodrug S, Kitada S, Hanada M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23-52.
127. Ito T, Deng X, Carr R, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272: 11671-11675.
128. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis, J Biol Chem 1998; 273: 25436-25442.
129. Deng X, Ito T, Carr B, Mumby M, May WS. Reversible phosphorylation of Bcl-2 following IL-3 or bryostatin is mediated by interaction of PP2A. J Biol Chem 1998; 271: 34157-34163.
130. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. Biol Chem 1994; 269: 26865-26870.
131. Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA, Makowski L. Screening of a library of phage-displayed peptides identifies human bcl1-2 as a taxol-binding protein. J Mol Biol 1999; 285: 197-203.
132. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptsis and phosphorylation of the Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996; 56: 1851-1854.
133. Blagosklonny MV, Chuman Y, Bergan RC, Fojo T. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bc1-2 phosphorylation and apoptosis in leukemia cells. Leukemia 1999; 13: 1028-1036.
134. Hu ZB, Minden MD, McCulloch EA. Phosphorylation of Bcl-2 after exposure of human leukemic cells to retinoic acid. Blood 1998; 92: 1768-1775.
135. Haldar S, Jena N, Croce C. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92: 4507-4511.
136. Haldar S, Chintapilli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-1255.
137. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-233.
138. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998; 58: 1609-1615.
139. Basu A, Haldar S. Microtubule-damagin drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of be 12 protein. Int J Oncol 1998; 13: 659-664.
140. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998; 18: 5509-3517.
141. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-3780.